Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 Biomarker disease BEFREE The aim of this paper was to report the most pivotal trials that evaluated different families of targeted therapy in the treatment of BC, according to their biomarkers (FGFR3, EGFR, HER2, VEGF and PI3K/AKT/mTOR). 30977669 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE PATIENT SUMMARY: We propose that APOBEC-mediated mutagenesis can generate clinically relevant driver mutations even within suboptimal motifs, such as in the case of FGFR3 S249C, one of the most common mutations in bladder cancer. 30975452 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE The FGFR3<sup>S249C</sup> mutation may therefore be used as a predictor of chemosensitivity in patients with BCa. 31316618 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 Biomarker disease BEFREE Hsa_circ_0068871 regulates the miR-181a-5p/FGFR3 axis and activates STAT3 to promote BCa progression, and it may serve as a potential biomarker. 30999937 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 Biomarker disease BEFREE In particular the Survivin-CD44 correlation was associated to HG FGFR3 wild type BCs (p = 0.0045). 30650148 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE Recent precision medicine has shown that mutations in BC are frequently observed in FGFR3, RAS and PIK3CA genes, all of which correlate with RAS signaling networks. 31066120 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer. 31377167 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 Biomarker disease BEFREE Regarding the association between mutated FGFR3 and bladder cancer, we found an OR 31 95% CI (15-64). 31028457 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE Silencing or inhibition of mutant FGFR3 in bladder cancer cell lines is associated with decreased malignant potential, confirming its important driver role in UC. 30952872 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 Biomarker disease BEFREE Human bladder cancer T24 and 5637 cell lines were transiently transfected with FGFR3-AS1-specific siRNA or negative control siRNA. 29226855 2018
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 Biomarker disease BEFREE Here we show that HDAC6 loss or inhibition reduces FGFR3 accumulation in cells made tumorigenic by ectopic expression of a mutant activated version of FGFR3 together with the MYC oncoprotein and in a bladder cancer cell line whose tumorigenicity is dependent on expression of a translocated version of FGFR3. 29423038 2018
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 AlteredExpression disease BEFREE We discovered a positive feedback loop, in which the activation of p38 and AKT downstream from the altered FGFR3 upregulates <i>MYC</i> mRNA levels and stabilizes MYC protein, respectively, leading to the accumulation of MYC, which directly upregulates <i>FGFR3</i> expression by binding to active enhancers upstream from <i>FGFR3</i> Disruption of this FGFR3/MYC loop in bladder cancer cell lines by treatment with FGFR3, p38, AKT, or BET bromodomain inhibitors (JQ1) preventing <i>MYC</i> transcription decreased cell viability <i>in vitro</i> and tumor growth <i>in vivo</i> A relevance of this loop to human bladder tumors was supported by the positive correlation between <i>FGFR3</i> and <i>MYC</i> levels in tumors bearing <i>FGFR3</i> mutations, and the decrease in FGFR3 and MYC levels following anti-FGFR treatment in a PDX model bearing an <i>FGFR3</i> mutation. 29463565 2018
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 Biomarker disease BEFREE High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. 29525349 2018
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 Biomarker disease BEFREE These results suggested for the first time that fluazuron is a potential inhibitor of FGFR3 and a candidate anticancer drug for the treatment of BC. 27664399 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 Biomarker disease BEFREE FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study. 28049011 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 AlteredExpression disease BEFREE Further investigation showed that FGFR3 knockdown resulted in downregulation of DAPK1 in bladder cancer cell line, suggesting that FGFR3 may be an upstream factor of DAPK1. 28388658 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE The present study examined the utility of fibroblast growth factor receptor 3 (<i>FGFR3</i>) mutation status and gene expression as a prognostic marker in primary pT1 bladder cancer (BC). 28927152 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE The GSE41035 dataset downloaded from Gene Expression Omnibus was used to identify the differentially expressed genes (DEGs) between bladder cancer cell line RT112 with or without depletion of FGFR3, and gene ontology enrichment analysis was performed. 28320388 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 AlteredExpression disease BEFREE Increased levels of FGFR3 and PIK3CA mutated DNA in urine and plasma are indicative of later progression and metastasis in bladder cancer. 28069289 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE Analysing only previously reported point mutations, TERT mutations were found in 55% of patients with bladder cancer (independent of stage), FGFR3 mutations in 30% of patients with bladder cancer, PIK3CA in 14% and TP53 mutations in 12% of patients with bladder cancer. 26901314 2016
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE In non-invasive BC, these mutations were related to high risk and grade (p<0.0001) as well as progression to muscle-invasive disease (p=0.01), whereas FGFR3 mutations were observed in low-grade BC (p=0.02) and patients with recurrences (p=0.05). 27611947 2016
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 AlteredExpression disease BEFREE Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer. 27356691 2016
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE FGFR3 mutations are common in low-grade BC, while TP53 mutation or loss of RB1 is associated with muscle-invasive BC. 26924873 2016
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE Search terms included 'FGFR3 genomic alterations' and 'urothelial cancer' or 'bladder cancer'. 27271022 2016
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.500 GeneticVariation disease BEFREE We assessed the performance of associating a FGFR3 mutation assay and a DNA methylation analysis to improve bladder cancer detection and to predict disease recurrence of NMIBC patients. 27586786 2016